摘要 |
The present application discloses a method to predict responsiveness of a patient, with cancer, to treatment with an angiogenesis inhibitor, such as for example bevacizumab and vanucizumab, said method comprising detecting frequency of mismatch repair (MMR) deficiency as a biomarker for predicting the patient's response to treatment. |